Education
About Us
Working with TipRanks
Follow Us
Kiniksa Pharmaceuticals (KNSA)
NASDAQ:KNSA
Total Valuation
Kiniksa Pharmaceuticals has a market cap or net worth of $1.56B. The enterprise value is $1.20B.
Market Cap$1.56B
Enterprise Value$1.20B
Share Statistics
Kiniksa Pharmaceuticals has 42,314,804 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding42,314,804
Owned by Insiders7.91%
Owned by Institutions0.68%
Financial Efficiency
Kiniksa Pharmaceuticals’s return on equity (ROE) is -0.10 and return on invested capital (ROIC) is -11.26%.
Return on Equity (ROE)-0.10
Return on Assets (ROA)-0.07
Return on Invested Capital (ROIC)-11.26%
Return on Capital Employed (ROCE)-0.10
Revenue Per Employee1.34M
Profits Per Employee-137.12K
Employee Count315
Asset Turnover0.73
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kiniksa Pharmaceuticals is -32.71. Kiniksa Pharmaceuticals’s PEG ratio is 0.08.
PE Ratio-32.71
PS Ratio4.01
PB Ratio3.22
Price to Fair Value3.22
Price to FCF55.59
Price to Operating Cash Flow55.00
PEG Ratio0.08
Income Statement
In the last 12 months, Kiniksa Pharmaceuticals had revenue of 423.24M and earned -43.19M in profits. Earnings per share was -0.60.
Revenue423.24M
Gross Profit423.24M
Operating Income-45.62M
Pretax Income-36.15M
Net Income-43.19M
EBITDA-45.62M
Earnings Per Share (EPS)-0.60
Cash Flow
In the last 12 months, operating cash flow was 25.69M and capital expenditures -277.00K, giving a free cash flow of 25.41M billion.
Operating Cash Flow25.69M
Free Cash Flow25.41M
Free Cash Flow per Share0.60
Dividends & Yields
Kiniksa Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.72
52-Week Price Change15.15%
50-Day Moving Average21.13
200-Day Moving Average22.54
Relative Strength Index (RSI)53.37
Average Volume (3m)593.41K
Important Dates
Kiniksa Pharmaceuticals upcoming earnings date is Apr 29, 2025, TBA Not Confirmed.
Last Earnings DateFeb 25, 2025
Next Earnings DateApr 29, 2025
Ex-Dividend Date―
Financial Position
Kiniksa Pharmaceuticals as a current ratio of 3.30, with Debt / Equity ratio of 2.25%
Current Ratio3.30
Quick Ratio3.04
Debt to Market Cap<0.01
Net Debt to EBITDA3.81
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Kiniksa Pharmaceuticals has paid 7.04M in taxes.
Income Tax7.04M
Effective Tax Rate-0.19
Enterprise Valuation
Kiniksa Pharmaceuticals EV to EBITDA ratio is -27.16, with an EV/FCF ratio of 48.76.
EV to Sales2.93
EV to EBITDA-27.16
EV to Free Cash Flow48.76
EV to Operating Cash Flow48.23
Balance Sheet
Kiniksa Pharmaceuticals has $243.63M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$233.77M billion.
Cash & Marketable Securities$243.63M
Total Debt$0.00
Net Cash-$233.77M
Net Cash Per Share-$5.52
Tangible Book Value Per Share$5.91
Margins
Gross margin is 85.54%, with operating margin of -10.78%, and net profit margin of -10.21%.
Gross Margin85.54%
Operating Margin-10.78%
Pretax Margin-8.54%
Net Profit Margin-10.21%
EBITDA Margin-10.78%
EBIT Margin-10.78%
Analyst Forecast
The average price target for Kiniksa Pharmaceuticals is $34.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$34.20
Price Target Upside60.11% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast56.60%
EPS Growth Forecast-403.56%